Zymedyne Therapeutics
PrivateLast Round
Seed
Nov 6, 2025
Total Funding Raised
$1.13M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Zymedyne Therapeutics operates in Healthcare & Life Sciences and is based in Calgary. Its latest recorded funding round was a Seed round in November 2025.
Zymedyne Therapeutics is a biotechnology company that develops non-opioid, small-molecule treatments for chronic inflammatory and neuropathic pain.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Zymedyne Therapeutics Comparables
Compare Zymedyne Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Regulonix | 83% | |
| Centrexion Therapeutics | 77% | |
| Latigo Biotherapeutics | 74% |
For institutional investors. Book with your work email.
Zymedyne Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Nov 6, 2025 | ||||
| Grant | Nov 6, 2024 | ||||
| Grant | Nov 1, 2024 | ||||
| Grant | Dec 15, 2023 | ||||
| Grant | Jun 3, 2022 | ||||
Grant | Jan 18, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Zymedyne Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Macquarie University Incubator | Grant |
| National Research Council Canada Industrial Research Assistance Program (NRC IRAP) | Grant |
| Alberta Innovates | Grant |
| Innovate Calgary | Grant |
| National Research Council of Canada | Grant |
| University of Calgary | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 6, 2025
$73K round led by University of Calgary
- Jan 18, 2022
$2K grant round led by Alberta Neuroscience
For institutional investors. Book with your work email.
Zymedyne Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Zymedyne Therapeutics's valuation, stock price, and market status.
Is Zymedyne Therapeutics a public or private company?
Zymedyne Therapeutics is a private company.
What is the current stock price of Zymedyne Therapeutics?
Zymedyne Therapeutics is a private company, so its shares have no public market price. Caplight tracks Zymedyne Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Zymedyne Therapeutics worth (valuation)?
Valuation information for Zymedyne Therapeutics is not publicly available.
Can I buy Zymedyne Therapeutics stock?
Zymedyne Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Zymedyne Therapeutics's last funding round?
Zymedyne Therapeutics's most recent funding round was Seed on November 6, 2025.
Who are the main investors in Zymedyne Therapeutics?
Key investors in Zymedyne Therapeutics include Macquarie University Incubator, Alberta Innovates, Innovate Calgary, National Research Council of Canada, University of Calgary.
Will Zymedyne Therapeutics IPO soon?
No public IPO plans have been announced for Zymedyne Therapeutics.
How can I track Zymedyne Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Zymedyne Therapeutics's shares on secondary markets.